“In our pharmacy and consumer wellness segment, we now project adjusted operating income to increase by $100 million to $150 million, or to $5.7 billion to $5.75 billion.”

In context

“e, our outlook now reflects a provision for potential variability in our 2024 risk adjustment position as our data matures over the remainder of the calendar year. As noted, we believe this variability has been appropriately reflected in our recently updated pricing for 2025. In our health services segment, we are increasing our estimates for 2024 adjusted operating income by a range of $200 million to $250 million, or $7.2 billion to $7.25 billion. This increase reflects the return to strong performance in our pharmacy services business in the second quarter, as well as the continuation of this exceptional execution through the remainder of the year. There is no change to the outlook for our healthcare delivery assets as these businesses continue to perform in line with our expectations. In our pharmacy and consumer wellness segment, we now project adjusted operating income to increase by $100 million to $150 million, or to $5.7 billion to $5.75 billion. While we recognize that there have been macro shifts in the economic and consumer dynamics, our pharmacy and consumer wellness segment continues to highlight the importance of our community health locations to the consumers we serve, reflected in our growing pharmacy market share. As a result, we are pulling some of the strong first half performance into our expectations for the full year. Finally, we updated our expectation for cash flow from operations to approximately $9 billion in 2024. This decrease is primarily driven by the timing of reinsurance premiums from CMS primarily related to our standalone prescription drug products, and the impact of lower HCB earnings. The Part D receivable increase will be repaid by CMS during the fourth quarter of 2025. You can find additional details”